Effects of Acetaminophen Exposure on Outcomes of Patients Receiving Immune Checkpoint Inhibitors for Advanced Non-Small-Cell Lung Cancer: A Propensity Score-Matched Analysis

被引:3
|
作者
Nelli, Fabrizio [1 ]
Virtuoso, Antonella [1 ]
Giannarelli, Diana [2 ]
Fabbri, Agnese [3 ]
Berrios, Julio Rodrigo Giron [3 ]
Marrucci, Eleonora [3 ]
Fiore, Cristina [3 ]
Ruggeri, Enzo Maria [3 ]
机构
[1] Cent Hosp Belcolle, Dept Oncol & Hematol, Thorac Oncol Unit, I-01100 Viterbo, Italy
[2] Fdn Policlin Univ A Gemelli, Ist Ricovero & Cura Carattere Sci IRCCS, Biostat Unit, Sci Directorate, I-00168 Rome, Italy
[3] Cent Hosp Belcolle, Dept Oncol & Hematol, Med Oncol Unit, I-01100 Viterbo, Italy
关键词
non-small-cell lung cancer; immune checkpoint inhibitors; first-line therapy; second-line therapy; acetaminophen; disease control benefit; survival; NONSMALL; ASSOCIATION; RESPONSES; SURVIVAL; EFFICACY; CRITERIA; RECIST;
D O I
10.3390/curroncol30090589
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
(1) Background: Several studies have investigated potential interactions between immune checkpoint inhibitors (ICIs) and commonly prescribed medications. Although acetaminophen (APAP) has not been considered susceptible to interaction with ICIs, recent research has shown that detectable plasma levels of this drug can hinder the efficacy of PD-1/PD-L1 blockade therapies. A reliable assessment of the potential interaction between APAP and ICIs in advanced non-small cell lung cancer (NSCLC) patients would be worthwhile since it is often prescribed in this condition. We sought to evaluate the impact of the concomitant use of APAP in patients with advanced NSCLC on PD-1/PD-L1 blockade using real-world evidence. (2) Methods: This study included consecutive patients with histologically proven stage IV NSCLC who underwent first-line therapy with pembrolizumab as a single agent or in combination with platinum-based chemotherapy, or second-line therapy with pembrolizumab, nivolumab, or atezolizumab. The intensity of APAP exposure was classified as low (therapeutic intake lasting less than 24 h or a cumulative intake lower than 60 doses of 1000 mg) or high (therapeutic intake lasting more than 24 h or a total intake exceeding 60 doses of 1000 mg). The favorable outcome of anti-PD-1/PD-L1 therapies was defined by durable clinical benefit (DCB). Progression-free survival (PFS) and overall survival (OS) were relevant to our efficacy analysis. Propensity score matching (PSM) methods were applied to adjust for differences between the APAP exposure subgroups. (3) Results: Over the course of April 2018 to October 2022, 80 patients were treated with first-line pembrolizumab either as single-agent therapy or in combination with platinum-based chemotherapy. During the period from June 2015 to November 2022, 145 patients were given anti-PD-1/PD-L1 blockade therapy as second-line treatment. Subsequent efficacy analyses relied on adjusted PSM populations in both treatment settings. Multivariate testing revealed that only the level of APAP and corticosteroid intake had an independent effect on DCB in both treatment lines. Multivariate Cox regression analysis confirmed high exposure to APAP and immunosuppressive corticosteroid therapy as independent predictors of shorter PFS and OS in both treatment settings. (4) Conclusions: Our findings would strengthen the available evidence that concomitant intake of APAP blunts the efficacy of ICIs in patients with advanced NSCLC. The detrimental effects appear to depend on the cumulative dose and duration of exposure to APAP. The inherent shortcomings of the current research warrant confirmation in larger independent series.
引用
收藏
页码:8117 / 8133
页数:17
相关论文
共 50 条
  • [11] The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer
    Jacobi, Oded
    Landman, Yosef
    Reinhorn, Daniel
    Icht, Oded
    Sternschuss, Michal
    Rotem, Ofer
    Finkel, Inbar
    Allen, Aaron M.
    Dudnik, Elizabeth
    Goldstein, Daniel A.
    Zer, Alona
    ONCOLOGY, 2021, 99 (09) : 555 - 561
  • [12] Effects of epidural analgesia on cancer recurrence and long-term mortality in patients after non-small-cell lung cancer resection: a propensity score-matched study
    Wu, Hsiang-Ling
    Tai, Ying-Hsuan
    Chan, Min-Ya
    Tsou, Mei-Yung
    Chen, Hsiu-Hsi
    Chang, Kuang-Yi
    BMJ OPEN, 2019, 9 (05):
  • [13] Survival outcomes of patients with nonsmall cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors
    Baek, Yeon-Hee
    Kang, Eun Joo
    Hong, Soojung
    Park, Sohee
    Kim, Ju Hwan
    Shin, Ju-Young
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (08) : 1291 - 1300
  • [14] Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors
    Takamori, Shinkichi
    Takada, Kazuki
    Shimokawa, Mototsugu
    Matsubara, Taichi
    Fujishita, Takatoshi
    Ito, Kensaku
    Toyozawa, Ryo
    Yamaguchi, Masafumi
    Okamoto, Tatsuro
    Yoneshima, Yasuto
    Tanaka, Kentaro
    Okamoto, Isamu
    Tagawa, Tetsuzo
    Mori, Masaki
    LUNG CANCER, 2021, 152 : 27 - 33
  • [15] Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors
    Naidoo, Jarushka
    Johnson, Douglas B.
    Doran, Charlotte
    Wang, Yuexi
    Zhang, Yan
    Le, Trong Kim
    Hopson, Sari
    Dreyfus, Brian
    Lal, Lincy S.
    Vyas, Charmy
    Goldstein, Shay
    Izadi, Zara
    ONCOLOGIST, 2024,
  • [16] Impact of natremia on metastatic non small cell lung cancer patients receiving immune checkpoint inhibitors
    Catalano, Martina
    Fancelli, Sara
    Caliman, Enrico
    Mazzoni, Francesca
    Michelet, Marta Gatta
    Mancini, Silvia
    Manneschi, Clara
    Shabani, Sonia
    Napolitano, Brunella
    Pillozzi, Serena
    Antonuzzo, Lorenzo
    Roviello, Giandomenico
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [17] A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study
    Kazuki Takada
    Mototsugu Shimokawa
    Shinkichi Takamori
    Shinichiro Shimamatsu
    Fumihiko Hirai
    Tetsuzo Tagawa
    Tatsuro Okamoto
    Motoharu Hamatake
    Yuko Tsuchiya-Kawano
    Kohei Otsubo
    Koji Inoue
    Yasuto Yoneshima
    Kentaro Tanaka
    Isamu Okamoto
    Yoichi Nakanishi
    Masaki Mori
    BMC Cancer, 22
  • [18] Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors
    Li, Nijiao
    Zheng, Xuliang
    Gan, Jinyan
    Zhuo, Ting
    Li, Xiaohong
    Yang, Chuyi
    Wu, Yanbin
    Qin, Shouming
    CHINESE MEDICAL JOURNAL, 2023, 136 (21) : 2562 - 2572
  • [19] Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors
    Li Nijiao
    Zheng Xuliang
    Gan Jinyan
    Zhuo Ting
    Li Xiaohong
    Yang Chuyi
    Wu Yanbin
    Qin Shouming
    中华医学杂志英文版, 2023, 136 (21)
  • [20] Serum Inflammatory Dynamics as Novel Biomarkers for Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer With Bone Metastases
    Asano, Yohei
    Yamamoto, Norio
    Hayashi, Katsuhiro
    Takeuchi, Akihiko
    Kato, Satoshi
    Miwa, Shinji
    Okuda, Miho
    Matsumoto, Isao
    Yano, Seiji
    Demura, Satoru
    ANTICANCER RESEARCH, 2024, 44 (10) : 4493 - 4503